Details for Patent: 8,784,869

Which drugs does patent 8,784,869 protect, and when does it expire?

Patent 8,784,869 protects NATESTO and is included in one NDA.

This patent has twenty-eight patent family members in twenty-two countries.

Summary for Patent: 8,784,869

Title:	Controlled release delivery system for nasal applications and methods of treatment
Abstract:	This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Inventor(s):	Mattern; Claudia (Stans, CH)
Assignee:	Mattern Pharma AG (Vaduz, LI)
Application Number:	13/547,774
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Use;

Drugs Protected by US Patent 8,784,869

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,784,869

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	03025769	Nov 11, 2003

International Family Members for US Patent 8,784,869

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047722
Austria	319426
Australia	2004286781
Brazil	PI0416370
Canada	2541498
Germany	60303854
Denmark	1530965